Effects of Norepinephrine on Heart Function in Septic Shock
Cardiac Effects of Norepinephrine After the Initial Phase of Septic Shock
This study tests if norepinephrine can continue to help improve heart function in patients who have been in septic shock for over 24 hours.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 49 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Trial ID | NCT05761522 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the impact of norepinephrine on myocardial contractility and cardiac output in patients experiencing septic shock for more than 24 hours. It involves collecting clinical and biological parameters, as well as performing transthoracic echocardiography to assess various cardiac metrics. The study aims to determine whether norepinephrine continues to positively influence heart function beyond the initial treatment phase. By analyzing these effects, the research seeks to enhance understanding of cardiac responses in prolonged septic shock management.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who have been diagnosed with septic shock for more than 24 hours and have a mean arterial pressure below 65 mmHg.
Not a fit: Patients currently receiving Dobutamine, pregnant individuals, or those with a do-not-resuscitate decision may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with septic shock, potentially enhancing cardiac function and outcomes.
How similar studies have performed: Previous studies have indicated positive effects of norepinephrine on cardiac function in the early phases of septic shock, but this investigation into later phases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients \>18 years old * Septic shock after 24 hours from its diagnosis * MAP\<65 mmHg for which the physician in charge decided to increase NE Exclusion Criteria: * Patient under Dobutamine * Pregnancy * Do not resuscitation decision
Where this trial is running
Reims
- Chu Reims — Reims, France (Recruiting)
Study contacts
- Study coordinator: Olfa Hamzaoui
- Email: ohamzaoui@chu-reims.fr
- Phone: 3 10 73 69 73
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.